HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION 2 UNIT
HEPARIN SODIUM : 2 UNIT · DIN 01990748 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION?
HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION 2 UNIT contains HEPARIN SODIUM : 2 UNIT. It is listed in the Health Canada Drug Product Database under DIN 01990748, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 13-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION used for?
Indicated as an anticoagulant in hemodialysis procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01990748 |
|---|---|
| Brand name | HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION |
| Generic / active ingredient | HEPARIN SODIUM : 2 UNIT |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 2 UNIT |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B01AB01 HEPARIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Jun-2017 |
How is it administered?
Administered by intravenous infusion using an infusion pump. Priming fluid for hemodialysis should contain 2,000 USP heparin units/1,000 mL. Dosage adjusted to individual patient requirements.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 20°C and 25°C. Protect from freezing.
How is it supplied?
Single-dose flexible plastic containers: 500 mL (1000 USP Units) and 1000 mL (2000 USP Units).
Contraindications
Hypersensitivity to heparin/pork; history of HIT; inability to perform coagulation tests; uncontrollable active bleeding (except DIC).
Warnings and precautions
Hemorrhage risk; monitor for Heparin-induced thrombocytopenia (HIT/HITT); risk of epidural/spinal hematoma; potential for hyperkalemia and fluid/solute overload. Not for intramuscular use.
Is HEPARIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by B. BRAUN MEDICAL INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION
What can be used instead?
Other Canadian products sharing ATC code B01AB01 HEPARIN. 10 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN LEO 100UNIT/ML | 100 UNIT | LIQUID | LEO PHARMA INC | MARKETED | DIN 00727520 |
| HEPARIN LEO INJ 1000UNIT/ML | 1000 UNIT | LIQUID | LEO PHARMA INC | MARKETED | DIN 00453811 |
| HEPARIN SODIUM INJECTION USP | 10000 UNIT | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382326 |
| HEPARIN SODIUM INJECTION USP | 5000 UNIT / 0.5 ML | SOLUTION | STERIMAX INC | MARKETED | DIN 02548488 |
| HEPARIN SODIUM INJECTION USP | 5000 UNIT / 0.5 ML | SOLUTION | STERINOVA INC. | MARKETED | DIN 02456958 |
| HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE) | 1000 UNIT | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02303086 |
| HEPARIN SODIUM INJECTION, USP | 1000 UNIT | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02264315 |
| HEPARIN SODIUM INJECTION, USP | 10000 UNIT | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02392453 |
| HEPARIN SODIUM INJECTION, USP | 10000 UNIT | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02264307 |
| CALCILEAN INJ 20000UNIT/0.8ML | 20000 UNIT / .8 ML | LIQUID | ORGANON TEKNIKA CANADA INC. | CANCELLED POST MARKET | DIN 00740527 |
Who else supplies HEPARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HEPARIN appears in 6 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.